In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidneyToshiki Tsuboi(Yokkaichi Municipal Hospital), Shoichi Maruyama(Nagoya University)Molecular Therapy — Nucleic AcidsDecember 18, 202410.1016/j.omtn.2024.102387Cited by 10SaveCiteExport RISWatch citationsRelated PapersEstimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes|JAMA|2023|310The ISN/RPS 2016 classification predicts renal prognosis in patients with first-onset class III/IV lupus nephritis|Scientific Reports|2021|27Mesenchymal stem cells exert renoprotection via extracellular vesicle-mediated modulation of M2 macrophages and spleen-kidney network|Communications Biology|2022|17